Clinical data confirm the high expression of EGFR compared to normal tissues, especially in glioblastoma multiforme, as well as head and neck cancers, which include tongue squamous cell carcinoma, and slightly lower in prostate cancer. This evidence concerns the gene EGFR and prostate carcinoma.